{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:45:55Z","timestamp":1793202355093,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ymgme.2017.06.008","type":"journal-article","created":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T21:33:59Z","timestamp":1498080839000},"page":"177-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Heterogeneity in a large pedigree with Danon disease: Implications for pathogenesis and management"],"prefix":"10.1016","volume":"123","author":[{"given":"Jonathan C.P.","family":"Roos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna I.","family":"Hyry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ymgme.2017.06.008_bb0005","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa033349","article-title":"Glycogen storage diseases presenting as hypertrophic cardiomyopathy","volume":"352","author":"Arad","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2017.06.008_bb0010","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2006.10.073","article-title":"New disease taxonomy and therapeutic implications: cardiomyopathies: therapeutics based on molecular phenotype J","volume":"49","author":"Ashrafian","year":"2007","journal-title":"Am. Coll. Cardiol."},{"issue":"24","key":"10.1016\/j.ymgme.2017.06.008_bb0015","doi-asserted-by":"crossref","first-page":"e858","DOI":"10.1161\/CIRCULATIONAHA.105.591982","article-title":"A contemporary approach to hypertrophic cardiomyopathy","volume":"113","author":"Ho","year":"2006","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ymgme.2017.06.008_bb0020","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1161\/CIRCULATIONAHA.105.546481","article-title":"Danon disease as an under recognized cause of hypertrophic cardiomyopathy in children","volume":"112","author":"Yang","year":"2005","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ymgme.2017.06.008_bb0025","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/hrt.2003.029504","article-title":"Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey","volume":"90","author":"Charron","year":"2004","journal-title":"Heart"},{"issue":"18","key":"10.1016\/j.ymgme.2017.06.008_bb0030","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2165\/00003495-200767180-00005","article-title":"Clarke JT Treatment of lysosomal storage disorders: progress with enzyme replacement therapy","volume":"67","author":"Rohrbach","year":"2007","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.ymgme.2017.06.008_bb0035","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/GIM.0b013e31820ad795","article-title":"Natural history of Danon disease","volume":"13","author":"Boucek","year":"2011","journal-title":"Genet Med."},{"issue":"12","key":"10.1016\/j.ymgme.2017.06.008_bb0040","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.2009.371","article-title":"Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy","volume":"301","author":"Maron","year":"2009","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ymgme.2017.06.008_bb0045","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0002-9149(85)90399-6","article-title":"The king of hearts: analysis of 23 patients with hearts weighing 1,000grams or more","volume":"55","author":"Roberts","year":"1985","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"10.1016\/j.ymgme.2017.06.008_bb0055","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/WNL.31.1.51","article-title":"Lysosomal glycogen storage disease with normal acid maltase","volume":"31","author":"Danon","year":"1981","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ymgme.2017.06.008_bb0060","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/mus.20471","article-title":"Novel Lamp-2 gene mutation and successful treatment with heart transplantation in a large family with Danon disease","volume":"33","author":"Echaniz-Laguna","year":"2006","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1016\/j.ymgme.2017.06.008_bb0070","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.2009.371","article-title":"Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy","volume":"301","author":"Maron","year":"2009","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.ymgme.2017.06.008_bb0075","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1056\/NEJM200506163522417","article-title":"Glycogen storage diseases and cardiomyopathy","volume":"352","author":"Roos","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"30","key":"10.1016\/j.ymgme.2017.06.008_bb0125","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","article-title":"A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)","volume":"35","author":"O'Mahony","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymgme.2017.06.008_bb0130","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1253\/circj.CJ-10-0837","article-title":"Prognostic role of high-sensitivity cardiac troponin T in patients with nonischemic dilated cardiomyopathy","volume":"75","author":"Kawahara","year":"2011","journal-title":"Circ. J."},{"issue":"14","key":"10.1016\/j.ymgme.2017.06.008_bb0135","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.jacc.2013.03.055","article-title":"Significance of high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy","volume":"62","author":"Kubo","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.ymgme.2017.06.008_bb0145","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1540-8183.2010.00575.x","article-title":"Marathon running as a cause of troponin elevation: a systematic review and meta-analysis","volume":"23","author":"Regwan","year":"2010","journal-title":"J. Interv. Cardiol."},{"key":"10.1016\/j.ymgme.2017.06.008_bb0150","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1532-429X-11-12","article-title":"Cardiovascular magnetic resonance findings in a case of Danon disease","volume":"11","author":"Piotrowska-Kownacka","year":"2009","journal-title":"J. Cardiovasc. Magn. Reson."},{"issue":"11","key":"10.1016\/j.ymgme.2017.06.008_bb0155","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1177\/0883073810367683","article-title":"End-stage cardiac disease as an initial presentation of systemic myopathies: case series and literature review","volume":"25","author":"Katzberg","year":"2010","journal-title":"J. Child. Neurol."},{"issue":"5","key":"10.1016\/j.ymgme.2017.06.008_bb0160","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/CIRCHEARTFAILURE.114.001105","article-title":"Danon disease: clinical features, evaluation, and management","volume":"7","author":"D'souza","year":"2014","journal-title":"Circ Heart Fail."},{"issue":"18","key":"10.1016\/j.ymgme.2017.06.008_bb0190","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1136\/heartjnl-2011-300048","article-title":"UK guidelines for referral and assessment of adults for heart transplantation","volume":"97","author":"Banner","year":"2011","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.ymgme.2017.06.008_bb0195","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF03086123","article-title":"Guidelines for heart transplantation","volume":"16","author":"de Jonge","year":"2008","journal-title":"Neth. Hear. J."},{"issue":"9","key":"10.1016\/j.ymgme.2017.06.008_bb0200","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.healun.2006.06.008","article-title":"Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates\u20142006","volume":"25","author":"Mehra","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.ymgme.2017.06.008_bb0210","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.healun.2003.10.019","article-title":"Should stable UNOS status 2 patients be transplanted?","volume":"24","author":"Jimenez","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.ymgme.2017.06.008_bb0215","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jacc.2003.10.035","article-title":"Frequency and impact of delayed decisions regarding heart transplantationnon long-term outcomes in patients with advanced heart failure","volume":"43","author":"Lewis","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymgme.2017.06.008_bb0235","unstructured":"Eisen HJ. Patient information: heart transplantation (beyond the basics). Up-to-date. 10-2-14. http:\/\/www.uptodate.com\/contents\/heart-transplantation-beyond-the-basics. Last accessed 27\/01\/16."},{"key":"10.1016\/j.ymgme.2017.06.008_bb0240","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1750-1172-8-135","article-title":"The legal imperative for treating rare disorders","volume":"8","author":"Hyry","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2017.06.008_bb0245","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/qjmed\/hcu240","article-title":"Orphan drugs: expensive yet necessary","volume":"108","author":"Hyry","year":"2015","journal-title":"QJM"},{"key":"10.1016\/j.ymgme.2017.06.008_bb0255","series-title":"Justice as Fairness: Restatement","author":"Rawls","year":"2001"},{"issue":"5\u20136","key":"10.1016\/j.ymgme.2017.06.008_bb0270","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.mam.2006.08.005","article-title":"Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy","volume":"27","author":"Eskelinen","year":"2006","journal-title":"Mol. Asp. Med."},{"issue":"11","key":"10.1016\/j.ymgme.2017.06.008_bb0275","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/hmg\/10.11.1215","article-title":"Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis","volume":"10","author":"Blair","year":"2001","journal-title":"Hum. Mol. Genet."},{"issue":"10","key":"10.1016\/j.ymgme.2017.06.008_bb0280","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/S0735-1097(02)03009-7","article-title":"Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy","volume":"41","author":"Crilley","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.ymgme.2017.06.008_bb0290","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2004.01.011","article-title":"Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts","volume":"82","author":"L\u00fccke","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.06.008_bb0295","first-page":"437","article-title":"Maternally inherited hypertrophic cardiomyopathy due to a novel T-to-C transition at nucleotide 9997 in the mitochondrial tRNA-glycine gene","volume":"55","author":"Merante","year":"1994","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2017.06.008_bb0300","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0735-1097(03)00300-0","article-title":"A homoplasmic mitochondrial transfer ribonucleic acid mutation as a cause of maternally inherited hypertrophic cardiomyopathy","volume":"41","author":"Taylor","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymgme.2017.06.008_bb0305","doi-asserted-by":"crossref","first-page":"12239","DOI":"10.1073\/pnas.220403797","article-title":"Yee AJ, et al Frataxin activates mitochondrial energy conversion and oxidative phosphorylation","volume":"97","author":"Ristow","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ymgme.2017.06.008_bb0310","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/ng1097-215","article-title":"Aconitase and mitochondrial iron-sulfur protein deficiency in Friedreich ataxia","volume":"17","author":"R\u00f6tig","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymgme.2017.06.008_bb0330","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/35022604","article-title":"Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease)","volume":"406","author":"Nishino","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2017.06.008_bb0325","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/scientificamerican0508-74","article-title":"How cells clean house","volume":"298","author":"Deretic","year":"2008","journal-title":"Sci. Am."},{"issue":"11","key":"10.1016\/j.ymgme.2017.06.008_bb0315","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1242\/jcs.184770","article-title":"Danon disease \u2013 dysregulation of autophagy in a multisystem disorder with cardiomyopathy","volume":"129","author":"Rowland","year":"2016","journal-title":"J. Cell Sci."},{"issue":"12","key":"10.1016\/j.ymgme.2017.06.008_bb0320","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1212\/WNL.58.12.1773","article-title":"Clinicopathological features of genetically confirmed Danon disease","volume":"58","author":"Sugie","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2017.06.008_bb0335","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/hmg\/9.2.275","article-title":"Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia","volume":"9","author":"Bradley","year":"2000","journal-title":"Hum. Mol. Genet."},{"issue":"7","key":"10.1016\/j.ymgme.2017.06.008_bb0340","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrd3482","article-title":"Cancer: autophagy presents Achilles heel in melanoma","volume":"10","author":"Flemming","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.ymgme.2017.06.008_bb0345","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/nrd2272","article-title":"Murphy LO, et al potential therapeutic applications of autophagy","volume":"6","author":"Rubinsztein","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"issue":"23","key":"10.1016\/j.ymgme.2017.06.008_bb0350","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/CIRCULATIONAHA.107.737965","article-title":"Sirolimus and cardiac transplantation: is it the \"magic bullet\"?","volume":"116","author":"Mudge","year":"2007","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ymgme.2017.06.008_bb0355","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ophtha.2006.02.030","article-title":"Ophthalmic manifestations of Danon disease","volume":"113","author":"Prall","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymgme.2017.06.008_bb0360","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1161\/CIRCULATIONAHA.107.692996","article-title":"Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation","volume":"116","author":"Raichlin","year":"2007","journal-title":"Circulation"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217300252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217300252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T15:54:30Z","timestamp":1533657270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719217300252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1096719217300252"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.06.008","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogeneity in a large pedigree with Danon disease: Implications for pathogenesis and management","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}